Hemab Therapeutics Holdings, Inc. (COAG)
A forensic read on Hemab Therapeutics Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
What the filings flag
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Hemab Therapeutics Holdings, Inc.:
No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Jul 29, 2026. Forensic signals flag probability, not certainty.